CYPRESS BIOSCIENCE, INC.
San Diego, CA US
|CYPRESS BIOSCIENCE, INC. Patent applications|
|Patent application number||Title||Published|
|20110189777||METHODS AND COMPOSITIONS FOR IMPROVED DIAGNOSTIC ASSAYS - The present invention describes diagnostic calibration methods and related compositions for flow cytometry instruments using synthetic control particles as an internal reference standard. The invention provides synthetic control beads which substantially reduce the drawbacks of conventional control beads. Synthetic beads coated with C3, C4 or CR1 and a non-specific spacer protein such as ovalbumin provide a control bead without the positive reactivity seen in conventional BSA controls. The present invention further provides a buffer system containing non-specific blockers and assay performance enhancers that do not interfere with analyte detection. The invention provides advantageous improvements over prior instrument calibration procedures, and provides control beads that enable consistent, reproducible data for diagnostic assays using flow cytometry.||08-04-2011|
|20100233752||METHOD FOR DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY AND RESPONSE TO TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND OTHER AUTOIMMUNE DISEASES - The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus and drug-induced lupus erythematosus by measuring cell-based complement activation products in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products, such as C3||09-16-2010|
|20100159493||METHODS OF QUANTIFYING METHOTREXATE METABOLITES - The present invention provides a method for efficiently converting methotrexate polyglutamates to methotrexate in a cellular extract by contacting the cellular extract with gamma glutamyl hydrolase under conditions suitable for efficient conversion of methotrexate polyglutamates to methotrexate.||06-24-2010|
|20090265116||PREDICTION OF AN INDIVIDUAL'S RISK OF DEVELOPING RHEUMATOID ARTHRITIS - Methods for predicting the likelihood of development of rheumatoid arthritis for individuals that present with recent-onset undifferentiated arthritis. The methods are based on the determination of a set of clinical markers and/or parameters and determining a predicted risk for developing rheumatoid arthritis. Clinical markers and parameters that are decisive for the risk for developing rheumatoid arthritis may include serum levels of C-reactive protein, Rheumatoid factors, anti-CCP antibodies, anti-MCV as well as age, gender, localization of the joint complaints, length of morning stiffness, and number of tender and/or swollen joints or combinations thereof. The method may be performed by a computer. The invention further relates to a computer, a sample analyser and a computer program product for performing the method and a data carrier with the computer program product.||10-22-2009|
|20090105222||PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISORDERS, INCLUDING STRESS-RELATED DISORDERS - Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a preferred embodiment the compound is milnacipran and is prophylactically administered at an effective amount to delay or prevent stress-related disorders in an individual at risk.||04-23-2009|
|20080293820||METHODS FOR IMPROVING PHYSICAL FUNCTION IN FIBROMYALGIA - Methods for improving physical function in fibromyalgia syndrome by administering an NSRI such as milnacipran as disclosed.||11-27-2008|
Patent applications by CYPRESS BIOSCIENCE, INC.